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ABSTRACT   
Background: The Asthma Salford Lung Study demonstrated the effectiveness and safety of 
initiating once-daily inhaled fluticasone furoate/vilanterol (FF/VI) versus continuing usual 
care (UC) in asthma patients in UK primary care [1]. Here, we report a detailed analysis of 
patient-reported outcome (PRO) endpoints. 
Methods: Adults with symptomatic asthma maintained on inhaled corticosteroids (ICS)  
± long-acting beta2-agonists (LABA) were randomized 1:1 to initiate FF/VI (100[200]/25 µg) 
or continue UC. PROs were measured using the Asthma Control Test (ACT), Standardised 
Asthma Quality of Life Questionnaire (AQLQ [S]), Work Productivity and Activity Impairment: 
asthma questionnaire, and EQ-5D-3L questionnaire, at timepoints across the 12-month 
study period.  
Results: The individual components of ACT response (total score ≥20 or improvement from 
baseline ≥3) both contributed to the composite primary effectiveness endpoint at Week 24, 
with odds ratios favoring FF/VI over UC in both cases. Patients initiating FF/VI versus 
continuing UC were more likely to maintain/improve asthma control, regardless of baseline 
control status. The odds of patients being responders on AQLQ (S) total score and on 
individual AQLQ domains at Week 52 were significantly higher for FF/VI versus UC (all  
p < .001). FF/VI was associated with significantly greater reductions in overall work and 
activity impairment due to asthma (both p < .001), and a significantly greater change from 
baseline in EQ visual analogue scale score (p = .007), versus UC at Week 52. PRO findings 
were consistent across baseline ICS and ICS/LABA subsets. 
Conclusions: Initiation of FF/VI versus continuing UC was associated with consistent 
improvements in PROs. 
 
  
4                                                                                                                                              Svedsater et al. SLS asthma PROs msp R1_16May18 
 
Introduction 
Asthma is one of the most common chronic respiratory diseases, affecting more than 
300 million people worldwide [2] and approximately 5.4 million in the UK [3]. The clinical 
symptoms and airway obstruction that characterize asthma fluctuate widely over time and 
range from mild to profoundly disabling [4]. Acute exacerbations of asthma impose 
considerable morbidity on patients and constitute a major burden on healthcare resources 
[4]. Their unpredictable nature can impact patients' psychological well-being, particularly in 
causing feelings of anxiety and loss of control, and worsen patients’ quality of life (QoL) [5–
8].                                                                                                                                           
 The main goal of asthma treatment is to achieve asthma control and minimize the 
risk of exacerbations and side effects [4]; consequently, the main clinical focus tends to be 
on symptoms management. However, patients are often more concerned with how their 
symptoms make them feel and the impact that symptoms have on their everyday lives [8]. 
Therefore, as well as improving objective clinical outcomes, therapeutic interventions for 
asthma should also aim to improve patients’ health-related-QoL (HR-QoL) [9].  
In recent years, health care has moved towards a patient-centric approach, which 
considers patients' perspectives regarding the impact of disease and its treatment. Patient-
reported outcomes (PROs) are now widely used in clinical practice, and in clinical trials, to 
capture patients’ subjective perceptions of changes in health status (symptoms or function) 
and HR-QoL that occur as a result of treatment intervention [10–12]. PROs are measures of 
health status directly elicited from patients, without external interpretation, and usually take 
the form of short, self-completed questionnaires. Numerous PRO instruments have been 
developed for use in patients with asthma, but not all are validated [12]. Including PRO 
endpoints in asthma clinical trials can complement more traditional efficacy endpoints, such 
as lung function, and provide a more comprehensive picture of the response to treatment. 
However, a review of recently published asthma clinical trials found that fewer than 10% had 
included PRO evaluations and none had been conducted in a real-world setting [13].  
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Effectiveness studies are often favored over traditional double-blind, randomized 
controlled trials (RCTs) for conducting comprehensive PRO assessments to determine the 
real-world impact of treatment, because they more closely reflect routine clinical care [11]. 
The Salford Lung Study in asthma (SLS asthma), a 12-month, open-label RCT conducted in 
UK primary care, compared the effectiveness and safety of initiating fluticasone 
furoate/vilanterol (FF/VI) versus continuing usual care (UC) in patients with symptomatic 
asthma. The trial incorporated a number of PRO effectiveness endpoints and topline PRO 
data have been published previously [1]. Here, we expand on the primary analysis of SLS 
asthma, reporting additional PRO findings from the study to provide a comprehensive picture 
of the impact of initiating FF/VI versus continuing UC in the overall patient population, and in 
patient subsets defined by asthma maintenance therapy at baseline. In particular, we aim to 
provide new, more detailed information on the impact of treatment on the components (i.e. 
domains/individual items) of the various PROs included in the study and on the likelihood of 
patients maintaining or improving asthma control during the study period. 
Methods 
Study design and patients                                                                                                      
 The SLS asthma study design has been described previously [1]. Briefly, this 
prospective, 12-month, open-label, RCT was conducted across 74 general practice clinics in 
Salford and South Manchester, UK, between November 2012 and December 2016. Adults 
aged ≥ 18 years, with a general practitioner’s (GP’s) diagnosis of symptomatic asthma, who 
were receiving regular maintenance inhaler therapy with an inhaled corticosteroid (ICS) 
alone or in combination with a long-acting beta2-agonist (LABA), were included. Exclusion 
criteria were minimal. Patients were randomized 1:1 to initiate once-daily inhaled FF/VI (100 
µg/25 µg or 200 µg/25 µg) or to continue with their UC, with stratification according to 
baseline Asthma Control Test (ACT) score (≤ 15, 16–19 or ≥ 20) and baseline intended 
asthma maintenance therapy (ICS or ICS/LABA); follow up was for 12 months. 
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The SLS asthma study was designed to mimic routine clinical practice, with minimal 
disruption to patients’ everyday lives, and treatment modifications were permitted at GPs’ 
discretion throughout the study in both treatment groups. There were few protocol-mandated 
clinic visits (screening, randomization and 12 months/early withdrawal visit only) and data 
were collected continuously and remotely via patients’ electronic health records using an 
integrated primary and secondary care-linked database system.                                               
 All patients provided written informed consent. The study was conducted in 
accordance with the International Conference on Harmonisation, Good Clinical Practice 
(ICH-GCP) and the Declaration of Helsinki, 2008. The study was approved by the National 
Research Ethics Service Committee North West, Greater Manchester South (approval 
number: 12/NW/0455). 
PRO questionnaires 
Asthma Control Test                                                                                                 
 The ACT is a validated, self-administered questionnaire, including for use over the 
telephone [14]. It comprises 5 questions that assess asthma control during the past 4 weeks 
on a 5-point categorical scale with the total score calculated as the sum of the scores from 
all 5 questions (range 5–25) [15]. Questions evaluate the effect of asthma on daily 
functioning, frequency of shortness of breath, frequency of asthma symptoms leading to 
night-time awakenings, frequency of rescue medication use, and overall self-assessment of 
asthma control. A higher total ACT score indicates better asthma control: ‘well controlled’,     
≥ 20 points; ‘partially controlled’, 16–19 points; ‘uncontrolled’, ≤ 15 points. The minimally 
important difference (MID) for ACT is 3 points [16]. The ACT was completed at baseline 
(randomization) and at Weeks 12, 24, 40, and 52/early withdrawal visit. Patients completed 
the questionnaire electronically at baseline and the Week 52/early withdrawal visit (as these 
were the protocol-mandated study visits), and over the telephone at Weeks 12, 24, 40 
(questionnaire conducted remotely so as to preserve the real-world nature of the trial). 
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Standardised Asthma Quality of Life Questionnaire                                                                            
 The Standardised Asthma Quality of Life Questionnaire (AQLQ [S]), a modified 
version of the original AQLQ, is a validated, disease-specific, self-administered 
questionnaire [17, 18] designed to evaluate the impact of asthma treatment on patients’ QoL 
over the past 2 weeks. The AQLQ (S) comprises 32 items in 4 domains (activity limitation 
[11 items], symptoms [12 items], emotional function [5 items], environmental stimuli [4 
items]) that are each rated on a 7-point scale, where 1 = total impairment and 7 = no 
impairment. The AQLQ (S) total score is calculated as the mean of all 32 items in the 
questionnaire and each individual domain score is calculated as the mean of the items within 
that domain. Therefore, the total and domain scores are also each defined on a range from 
1–7 with higher scores indicating better QoL. The MID for overall or domain-specific QoL is 
0.5 points [19]. The AQLQ (S) was completed at baseline, at Week 24, and at the Week 
52/early withdrawal visit; electronically at baseline and Week 52/early withdrawal visit, and 
by telephone at Week 24. 
Work Productivity and Activity Impairment: asthma                                                          
 The Work Productivity and Activity Impairment (WPAI): asthma questionnaire is a 
validated, self-administered, 6-item questionnaire [20, 21] designed to quantitatively assess 
patients’ overall work impairment and overall activity impairment due to asthma during the 
past 7 days. Four types of asthma-derived scores are calculated: absenteeism (work time 
missed); presenteeism (impairment at work/reduced on-the-job effectiveness); work 
productivity loss (overall work impairment/absenteeism plus presenteeism) and activity 
impairment. The WPAI: asthma questionnaire was completed electronically at baseline and 
at the Week 52/early withdrawal visit. 
EuroQol 5-Dimensions 3-Levels questionnaire                                                                 
 The EuroQol 5-Dimensions 3-Levels questionnaire (EQ-5D-3L) is a standardized, 
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self-administered instrument used to provide a simple, generic measure of patients’ health 
status “today” [22]. The questionnaire comprises 2 parts: the EQ-5D descriptive system and 
the EQ visual analogue scale (EQ VAS). The descriptive system covers 5 dimensions 
(mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each 
measured on a 3-point Likert scale (1 = no problems, 2 = some problems, and 3 = extreme 
problems). Based on patients’ selection of levels that reflect their "own health state today" for 
each of the 5 dimensions, 1 of 243 distinct health states can be assigned and a single utility 
score calculated, ranging from 0–1. A higher utility score is indicative of better QoL. For the 
EQ VAS, patients rate their current health status by selecting a score on a continuous 
vertical visual scale ranging from 0 = worst imaginable health state to 100 = best imaginable 
health state. The EQ-5D-3L questionnaire was completed electronically at baseline and at 
the Week 52/early withdrawal visit. 
Study endpoints                                                                                                                 
 Pre-planned PRO endpoints included: the percentage of ACT responders at Week 24 
(responders defined as patients who achieved an ACT total score of ≥ 20 and/or an 
improvement from baseline of ≥ 3; composite primary effectiveness endpoint); the relative 
contributions of the individual components of ACT total score ≥ 20 or improvement from 
baseline ≥ 3 to the composite primary effectiveness endpoint at Week 24; mean change 
from baseline in ACT score at Week 24; transitional probability of patients’ ACT control 
status in any visit (Weeks 12, 24, 40, and 52) according to control status at the previous visit, 
and probability of control status in a recorded visit according to control status at the previous 
visit; mean change from baseline in AQLQ (S) total score and domain scores at Week 52; 
percentage of AQLQ (S) responders (defined as patients with an increase from baseline of ≥ 
0.5 points at Week 52) for total score and the environmental stimuli domain; mean change 
from baseline in WPAI: asthma-derived scores at Week 52; and EQ-5D-3L health status at 
Week 52.                                                                                                                                       
 Post-hoc analyses were conducted for the percentage of AQLQ (S) responders 
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(patients with an increase from baseline of ≥ 0.5 points at Week 52) for the symptoms, 
activity limitation, and emotional function domains. 
Statistical analyses 
Analysis populations                                                                                                               
 All analyses were conducted according to the intention-to-treat (ITT) principle. The 
overall study population included all randomized patients who received at least 1 prescription 
of study medication (FF/VI or UC). The primary effectiveness analysis (PEA) population 
included all patients in the overall study population with a baseline ACT score of < 20. 
Subsets of the overall and PEA populations defined by baseline intended asthma 
maintenance therapy (ICS or ICS/LABA) were also analyzed; these included patients whose 
asthma maintenance therapy at baseline per randomization stratification and whose pre-
randomization prescription was either ICS alone or ICS/LABA (fixed dose combination or in 
separate inhalers).  
PRO analyses                                                                                                                         
 The percentage of ACT responders based on the composite primary endpoint at 
Week 24 was analyzed in the overall PEA population and corresponding ICS and ICS/LABA 
subsets. A supporting analysis in the overall study population was also conducted. The 
percentage of patients achieving either the threshold of ≥ 20 points for ‘well controlled’ 
asthma or achieving the MID for ACT of ≥ 3 points at Week 24 were determined separately 
for each population. Statistical analyses were conducted using logistic regression.                 
 ACT transitional probabilities were analyzed in the overall study population and 
corresponding ICS and ICS/LABA subsets. A PEA sensitivity analysis was also conducted. 
Using a Markov chain method, the probabilities of patients transitioning from one state of 
asthma control to another based on ACT score at a given time point were determined for the 
FF/VI and UC treatment groups (e.g., the probability of patients transitioning from an 
uncontrolled state to a partially controlled state or a well-controlled state, etc). Probabilities 
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were calculated using an ordinal logistic regression model [23]; summary statistics were 
descriptive only. 
AQLQ (S) responder analyses at Week 52 were performed in the overall study 
population and corresponding ICS and ICS/LABA subsets using logistic regression. Mean 
change from baseline in WPAI: asthma-derived scores at Week 52 were analyzed in the 
overall study population and corresponding ICS and ICS/LABA subsets. Statistical analyses 
were performed using analysis of covariance (ANCOVA). EQ-5D-3L analyses were 
performed in the overall study population and corresponding ICS and ICS/LABA subsets. 
The percentage of responders (patients self-scoring 1 = no problems) for each of the 5 
descriptive domains was calculated for FF/VI and UC and between-group differences were 
analyzed using logistic regression. Least squares (LS) mean change from baseline to Week 
52 in EQ-5D-3L utility and EQ VAS scores were also calculated, and between-group 
differences were determined using ANCOVA.  
Results 
Patients  
In total, 4233 patients (2114 FF/VI; 2119 UC) were included in the overall study 
population. Patient demographics and baseline characteristics have been reported 
previously; these were well matched between the treatment groups [1]. Briefly, patients had 
a mean (standard deviation [SD]) age of 50 (16) years and 59% were female. Mean (SD) 
body mass index was 30 (7) kg/m2 and 53% were current or former smokers. Most patients 
(87%) had been diagnosed with asthma at least 5 years previously; 90% experienced 
daytime symptoms at least twice weekly and 36% had experienced at least 1 exacerbation in 
the year before randomization. In total, 3026 (71%) patients in the overall study population 
had a baseline ACT score < 20 and were included in the PEA population (1512 FF/VI; 1514 
UC). 
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ACT – Individual questions 
 A summary of patients’ responses to the five individual questions of the ACT by 
treatment group at Week 24 is provided in Supplementary Table 1 (overall study population 
and corresponding ICS and ICS/LABA subsets, plus PEA population). Findings were 
consistent across the individual ACT questions for the different populations analysed. 
 
ACT composite analysis        
 Analysis of the percentage of patients who achieved either an ACT total score ≥ 20 
or an improvement from baseline of ≥ 3 points at Week 24 demonstrated that both individual 
measures contributed to the composite primary effectiveness endpoint in SLS asthma. Odds 
ratios (ORs) favored FF/VI over UC in both cases (PEA population, ACT total score ≥ 20: 
OR 1.98 [95% confidence interval (CI): 1.69–2.33]; improvement from baseline ≥ 3 points: 
OR 2.05 [95% CI: 1.75–2.40]) consistent with the primary analysis [1]. Similar results were 
observed for the ICS and ICS/LABA subsets of the PEA population (Table 1). Findings were 
also consistent in the overall study population (data not shown).
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Table 1 
Contribution of ACT total score ≥ 20 and improvement from baseline ≥ 3 to the composite primary effectiveness endpoint in SLS asthma (Week 24 




Patients, n/N (%)a 
Overall PEA population  ICS subset ICS/LABA subset 
FF/VI 
n = 1512 
UC 
n = 1514 
Adjusted OR  
(95% CI)b 
FF/VI 
n = 484 
UC 
n = 492 
Adjusted OR  
(95% CI)c 
FF/VI 
n = 997 
UC 
n = 989 
Adjusted OR  
(95% CI)c 
ACT total score ≥ 20 and/or 






















637/908   
(70) 
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aPercentages based on a denominator of the number of patients evaluable for ACT.  
bORs and 95% CIs for the difference between FF/VI and UC were determined using a logistic regression model adjusted for randomized treatment, baseline ACT total score, baseline ACT total 
score squared (composite endpoint only), asthma maintenance therapy at baseline per randomization stratification, age, and gender.  
cFor analysis of the ICS and ICS/LABA subsets of the PEA population, the statistical models did not include the asthma maintenance therapy at baseline per randomization stratification variable. 
Abbreviations: ACT, Asthma Control Test; CI, confidence interval; FF/VI, fluticasone furoate/vilanterol; ICS, inhaled corticosteroid; LABA, long-acting beta2-agonist; OR, odds ratio; PEA, primary 
effectiveness analysis; SLS, Salford Lung Study; UC, usual care.   
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ACT transitional probabilities         
 A higher proportion of patients initiating FF/VI versus continuing UC maintained or 
improved their asthma control during the study, regardless of control status at baseline (Fig. 
1, A). Similar findings were observed in the ICS and ICS/LABA subsets (Fig. 1, B, C). 
Conversely, patients continuing on UC were more likely to have worsening of asthma control 
(Supplementary Fig. 1) or to remain uncontrolled or partially controlled (Supplementary 
Fig. 2). Results were consistent in the PEA population (data not shown).   
 
 
Fig. 1. Transitional probabilities of maintaining or improving asthma control based on ACT scores measured 
across the 12-month study period.a,b (A) Overall study population, (B) ICS subset, (C) ICS/LABA subset. 
aTransitional probability of control status in any visit according to control status at the previous visit. bProbabilities 
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were calculated using an ordinal logistic regression model adjusted for randomized treatment and previous 
control status. (A) Overall study population: data based on n = 2052 patients in the FF/VI group and n = 2076 in 
the UC group contributing to at least 1 transition. (B) ICS subset: data based on n = 724 patients in the FF/VI 
group and n = 743 in the UC group contributing to at least 1 transition. (C) ICS/LABA subset: data based on n = 
1290 patients in the FF/VI group and n = 1296 in the UC group contributing to at least 1 transition. Abbreviations: 
FF/VI, fluticasone furoate/vilanterol; PC, partially controlled; UC, usual care; UnC, uncontrolled; WC, well 
controlled. 
 
Many patients showed improved asthma control early on in the trial, with the most prominent 
effect seen during the baseline to 12 weeks interval followed by a trend of stabilization 
thereafter (Supplementary Table 2; overall study population). Similar findings were 
observed in the ICS and ICS/LABA subsets of the overall study population (Supplementary 
Tables 3 and 4) and in the PEA population (data not shown). 
AQLQ (S) analyses          
 At baseline, mean total AQLQ (S) scores were 5.01 in the FF/VI group and 5.00 in 
the UC group (overall study population). At Week 52, mean scores had increased by 0.70 
and 0.42 points in the FF/VI and UC groups, respectively. At Week 52, 55% of patients 
initiated on FF/VI and 43% continuing on UC were classified as responders based on 
change from baseline ≥ 0.5 in AQLQ (S) total score (OR: 1.79 [95% CI: 1.55–2.06], p < .001) 
[1]. Similar findings with respect to the proportions of AQLQ (S) responders by treatment 
group were observed across all 4 individual AQLQ (S) domains, with ORs favoring FF/VI 
over UC in the overall study population and in the ICS and ICS/LABA subsets (OR range: 
1.51–1.92; all p < .001; Fig. 2). 
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Fig. 2. Statistical analysis of AQLQ (S) responders by individual domains with FF/VI versus UC (Week 52 data) a. 
aLogistic regression model adjusted for randomized treatment, baseline AQLQ (S) score, asthma maintenance 
therapy at baseline per randomization stratification, ACT total score at baseline per randomization stratification, 
age, and gender. For analysis of the ICS and ICS/LABA subsets of the overall study population, the statistical 
models did not include the asthma maintenance therapy at baseline per randomization stratification variable. 
Abbreviations: AQLQ (S), Standardized Asthma Quality of Life Questionnaire; CI, confidence interval; FF/VI, 
fluticasone furoate/vilanterol; ICS, inhaled corticosteroid; LABA, long-acting beta2-agonist; OR, odds ratio; UC, 
usual care.   
WPAI: asthma-derived scores        
 In the overall study population, mean baseline WPAI scores for FF/VI and UC, 
respectively, were 1.9% and 2.9% for work time missed, 15.4% and 16.1% for impairment 
while working, 15.8% and 16.8% for overall work impairment, and 28.1% and 28.4% for 
activity impairment. Initiating FF/VI was associated with statistically significantly greater 
reductions in impairment while working (difference -2.8% [95% CI: -4.3 to -1.3], p < .001), 
overall work impairment (difference -2.8% [95% CI: -4.4 to -1.1], p < .001), and activity 
impairment (difference -4.5% [95% CI: -5.9 to -3.2], p < .001) due to asthma, but not for work 
time missed due to asthma (difference -0.6% [95% CI: -1.7 to 0.4], p = .223), compared with 
continuing UC at Week 52. Similar results were observed in the ICS and ICS/LABA subsets 
(Table 2). 
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Table 2.  
 Statistical analysis of change from baseline in WPAI: asthma-derived scores (Week 52 data).a 
 
aData based on last available on-treatment measurement (Week 52 or early withdrawal visit).  
bBetween-group differences (FF/VI versus UC), 95% CIs, and associated p-values were calculated using an ANCOVA model adjusted for randomized treatment, asthma maintenance 








Overall study population ICS subset ICS/LABA subset 
LS mean change from 








LS mean change from 








LS mean change from 









(n = 2114) 
UC 
(n = 2119) 
FF/VI 
(n = 750) 
UC 
(n = 755) 
FF/VI 
(n = 1325) 
UC 
(n = 1325) 
Percent work time 
missed due to 
asthma 
n = 833 
 
-0.3 (0.38) 




(-1.7 to 0.4) 
 
p = .223 
n = 311 
 
-0.0 (0.62) 




(-2.0 to 1.3) 
 
p = .650 
n = 508 
 
-0.6 (0.45) 




(-1.8 to 0.8) 
 
p = .440 
Percent impairment 
while working due to 
asthma 
n = 823 
 
-6.9 (0.56) 




(-4.3 to -1.3) 
 
p < .001 
n = 305 
 
-5.7 (0.81) 




(-5.0 to -0.6) 
 
p = .011 
n = 503 
 
-7.4 (0.75) 




(-5.0 to -0.8) 
 
p = .007 
Percent overall work 
impairment due to 
asthma 
n = 822 
 
-6.7 (0.60) 




(-4.4 to -1.1) 
 
p < .001 
n = 305 
 
-5.6 (0.88) 
n = 335 
 
-2.8 (0.84)  
-2.9  
(-5.2 to -0.5) 
 
p = .018 
n = 503 
 
-7.1 (0.80) 




(-5.0 to -0.4) 
 
p = .019 
Percent activity 
impairment due to 
asthma 
n = 1982 
 
-10.4 (0.50) 




(-5.9 to -3.2) 
 
p < .001 
n = 696 
 
-8.5 (0.77) 




(-6.5 to -2.3) 
 
p < .001 
n = 1250 
 
-10.8 (0.65) 




(-6.6 to -3.0) 
 
p < .001 
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cFor analysis of the ICS and ICS/LABA subsets of the overall study population, the statistical models did not include the asthma maintenance therapy at baseline per randomization 
stratification variable.  
Abbreviations: ANCOVA, analysis of covariance; CI, confidence interval; FF/VI, fluticasone furoate/vilanterol; ICS, inhaled corticosteroid; LABA, long-acting beta2-agonist; LS, least 
squares; SE, standard error; UC, usual care; WPAI, work productivity and activity impairment. 
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EQ-5D-3L health status         
 At baseline, the proportions of responders for each of the 5 EQ-5D-3L descriptive 
dimensions appeared similar between the FF/VI and UC groups in the overall study 
population (Table 3). The odds of patients being responders at Week 52 were statistically 
significantly higher with FF/VI versus UC for the mobility (p < .001), usual activities (p = 
.027), and pain/discomfort (p =.043) dimensions, but not for the self-care (p = .409) and 
anxiety/depression (p = .180) dimensions (Table 3). Corresponding data for the ICS and 
ICS/LABA subsets of the overall study population are summarized in Supplementary 
Tables 5 and 6. 
Table 3 
Statistical analysis of the proportion of respondersa on individual EQ-5D-3L descriptive 










Baseline Week 52 
Patients, n/N (%) Patients, n/N (%)  





n = 2114 
UC 
n = 2119 
FF/VI 
n = 2114 
UC 
























p = .409 











p = .027 
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p = .180 
 
aResponders were defined as patients who self-scored 1 = no problems for a given dimension.  
bData based on last available on-treatment measurement (Week 52 or early withdrawal visit).  
cORs, 95% CIs, and p-values were calculated using a logistic regression model adjusted for randomized 
treatment, asthma maintenance therapy at baseline per randomization stratification, ACT total score at baseline 
per randomization stratification, gender, age, and the relevant baseline EQ-5D-3L domain score.   
Abbreviations: CI, confidence interval; EQ-5D-3L, EuroQol 5-Dimensions 3-Levels Questionnaire; FF/VI, 
fluticasone furoate/vilanterol; OR, odds ratio; UC, usual care. 
 
In the overall study population, the LS mean change in EQ-5D-3L utility score from baseline 
to Week 52 was 0.0170 for FF/VI and 0.0051 for UC; the between-group difference was not 
statistically significant (difference: 0.0119 [95% CI: -0.0017 to 0.0254]; p = .086) (Table 4). 
The LS mean change from baseline to Week 52 in EQ VAS score was 3.0 for FF/VI and 1.4 
for UC, with a statistically significant difference between the groups (difference 1.6 [95% CI: 
0.4–2.7]; p = .007). A similar treatment effect with FF/VI versus UC was also observed in the 
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Table 4 
Statistical analysis of change from baseline in EQ-5D-3L utility and VAS scores (Week 52 dataa). 
 Overall study population ICS subset ICS/LABA subset 
LS mean change from 
baseline (SE) 
Difference FF/VI 




LS mean change from 
baseline (SE) 
Difference FF/VI 




LS mean change from 
baseline (SE) 
Difference FF/VI 





(n = 2114) 
UC 
(n = 2119) 
FF/VI  




(n = 1325) 
UC 
(n = 1325) 
EQ-5D-3L 
utility score 












p = .086 












p = .161 












p = .189 
EQ VAS 
score 
n = 1984 
 
3.0 (0.43) 





(0.4 to 2.7) 
 
p = .007 
n = 696 
 
1.3 (0.70) 




(-0.2 to 3.6) 
 
p = .083 
n = 1252 
 
4.0 (0.54) 




(0.2 to 3.2) 
 
p = .024 
aData based on last available on-treatment measurement (Week 52 or early withdrawal visit).  
bBetween-group differences (FF/VI versus UC), 95% CIs, and p-values were calculated using an ANCOVA model adjusted for randomized treatment, asthma maintenance 
therapy at baseline per randomization stratification, ACT total score at baseline per randomization stratification, gender, age, and baseline EQ-5D-3L utility/VAS score (as 
appropriate).  
cFor analysis of the ICS and ICS/LABA subsets of the overall study population, the statistical models did not include the asthma maintenance therapy at baseline per 
randomization stratification variable. 
Abbreviations: ANCOVA, analysis of covariance; CI, confidence interval; EQ-5D-3L, EuroQol 5-Dimensions 3-Levels Questionnaire; EQ VAS, EuroQol visual analogue scale; 
FF/VI, fluticasone furoate/vilanterol; LS, least squares; SE, standard error; UC, usual care. 
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Discussion 
In this detailed analysis of prospectively collected PRO data from the SLS asthma 
study, we aimed to provide a fuller picture of the impact of initiating FF/VI versus continuing 
UC on asthma patients’ HR-QoL, and also to explore the impact of patients’ baseline asthma 
maintenance therapy (ICS or ICS/LABA) on PRO findings. The present work expands on the 
primary results of the SLS asthma study [1], demonstrating that the observed improvement 
in asthma control (as measured by ACT) with initiation of FF/VI versus continuing UC 
translates into patient-perceived benefits in HR-QoL (as measured by the AQLQ [S], work-
relevant WPAI: asthma, and EQ-5D-3L instruments).  
Analysis of the individual components of ACT total score ≥ 20 or improvement from 
baseline ≥ 3 demonstrated that both measures contributed to the composite primary 
effectiveness endpoint used in SLS asthma, with ORs favoring FF/VI versus UC in both 
cases. This suggests that the benefit of initiating FF/VI versus continuing UC on asthma 
control holds true both for patients achieving the threshold of ≥ 20 points for ‘well controlled’ 
asthma and for those achieving a change from baseline equating to the MID for ACT of ≥ 3 
points. The benefit of FF/VI versus UC was also observed across different ‘states’ of asthma 
control based on ACT scores. Results from the Markov transitional probability modeling 
suggest that patients initiated on FF/VI were more likely to maintain or improve asthma 
control during the 12-month study period compared with patients who continued on UC, 
irrespective of their asthma control status at baseline. Many patients showed improved 
asthma control early on in the trial, with the most prominent effect seen during the baseline 
to 12 weeks interval and a trend of stabilization thereafter. Although this effect was observed 
in both treatment groups, it is important to note that the treatment effect of FF/VI versus UC 
persisted throughout the 12-month study duration. 
The observed benefit of FF/VI versus UC at Week 52 for total AQLQ (S) score and 
across all 4 individual AQLQ (S) domains suggests an all-round more favorable impact of 
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initiating FF/VI versus continuing UC on patients’ HR-QoL. To note, there is some overlap in 
the concepts captured by the domains of AQLQ and in the questions comprising the ACT, 
supporting the consistency of our findings across different questionnaires/endpoints used in 
this study. The benefit of FF/VI over UC on PROs was also demonstrated for WPAI: asthma-
derived scores at Week 52, indicating a lesser impact of initiating FF/VI versus continuing 
UC on patients’ ability to work and carry out regular daily activities. While there is no 
reported MID for the WPAI: asthma questionnaire, our results for the magnitude of change 
from baseline to Week 52 in WPAI scores should be interpreted in the context of patients’ 
baseline impairment scores. 
In addition to the asthma-specific PRO tools used in the SLS asthma study, patients’ 
perceptions of generic health status were also recorded using EQ-5D-3L. At Week 52, the 
odds of patients being EQ-5D-3L responders were statistically significantly higher with 
initiating FF/VI versus continuing UC for 3 of the 5 descriptive domains (mobility, usual 
activities, and pain/discomfort); however, this did not translate into a significantly greater 
change from baseline to Week 52 in overall EQ-5D-3L utility scores with FF/VI versus UC. In 
contrast, patients initiating FF/VI had a statistically significantly greater improvement from 
baseline to Week 52 in EQ VAS score. 
The results for all evaluated PRO endpoints in the overall/PEA populations were 
consistent across the ICS and ICS/LABA subsets, supporting the benefit of FF/VI over UC 
regardless of patients’ baseline maintenance therapy. As baseline therapy is likely indicative 
of baseline asthma severity/degree of asthma control (with addition of LABA to ICS 
recommended as an option for patients whose asthma is uncontrolled on ICS alone [4]), the 
consistency of findings in these subsets suggests that the patient-perceived benefits of 
initiating FF/VI versus continuing UC may be relevant across different severities of disease, 
and also suggest that the results were not mediated by a step-up in treatment from ICS to 
ICS/LABA as part of the study design.        
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Although the SLS asthma study demonstrated improved asthma control (based on 
ACT) with initiation of FF/VI versus continuing UC, there was no observed between-group 
difference in asthma exacerbation rates in the overall SLS population [1]. It could be 
hypothesized, therefore, that the observed effects of FF/VI versus UC on PROs in the 
present study are not due to a reduction in exacerbations but instead due to an “everyday” 
effect on asthma control. In support of this, the PRO questionnaires utilized in this study 
recorded a range of outcomes (including asthma symptoms, impairment of function/activities 
of daily living, ability to work, and overall health status) and we observed a consistent 
treatment effect with FF/VI versus UC across the different domains/items of the various 
questionnaires. It was not possible, however, to pinpoint individual elements that may have 
been responsible for the observed results or that were predictive of positive outcomes; this 
may be of interest to explore in future studies. 
While our findings provide support for improved PROs with initiating FF/VI versus 
continuing UC, limitations of the reported analyses should also be considered including the 
open-label design of the trial and the potential for bias, as well as the post-hoc nature of a 
subset of the AQLQ (S) analyses. 
Although efficacy data from double-blind RCTs are typically used to inform clinical 
practice guidelines [24], patients enrolled in these studies tend to be highly selected and 
closely monitored, and therefore such trials are of limited relevance to patients seen in 
everyday clinical practice [25, 26]. There is now increasing interest in conducting prospective 
real-world studies to assess the comparative effectiveness of treatment interventions [27] 
and an increasing recognition of the value provided by PROs in guiding treatment decisions 
and informing health policy [12]. Our findings from SLS asthma add to the currently limited 
body of literature around the use of PROs in asthma clinical trials and on how asthma control 
is associated with patient-experienced benefits. Our findings may also have relevance for 
the everyday clinical management of patients with asthma. The very limited 
inclusion/exclusion criteria and minimal impact of trial procedures on patients’ everyday 
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lives/routine clinical care in SLS asthma lend support to the applicability of our findings to a 
broad population of patients with symptomatic asthma. Furthermore, the use of disease-
specific PRO instruments with validated MIDs in the study design allowed us to measure 
changes that are clinically meaningful to patients. Our results also underscore the 
importance validating findings from highly controlled asthma efficacy RCTs in real-world 
effectiveness studies [28]. 
Conclusions 
Overall, our findings suggest that initiating treatment with once-daily inhaled FF/VI provides 
not only better asthma control compared with continuing UC in patients with symptomatic 
asthma, but also results in consistent improvements in HR-QoL as perceived by patients, 
which are highly relevant factors for guiding asthma treatment. Furthermore, the observed 
effects of initiating FF/VI versus continuing UC on asthma control were shown to be 
consistent regardless of patients’ initial asthma control status. 
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Supplementary information 
Supplementary Table 1 
Summary of patients’ responses to individual questions of the ACT questionnaire by treatment group (Week 24 data). 
 
 
Patients, n (%) 
Overall study population PEA population ICS subseta,b ICS/LABA subseta,c 
FF/VI 
N = 2114 
UC 
N = 2119 
FF/VI 
N = 1512 
UC 
N = 1514 
FF/VI 
N = 750 
UC 
N = 755 
FF/VI 
N = 1325 
UC 
N = 1325 
Q1. Getting as much done at work, 
school, or home 
Evaluable, n 1936 1957 1373 1399 689 699 1214 1223 
1. All of the time 21 (1) 36 (2) 18 (1) 34 (2) 7 (1) 10 (1) 14 (1) 25 (2) 
2. Most of the time 97 (5) 133 (7) 90 (7) 126 (9) 23 (3) 42 (6) 72 (6) 89 (7) 
3. Some of the time 292 (15) 383 (20) 256 (19) 337 (24) 84 (12) 110 (16) 203 (17) 265 (22) 
4. A little of the time 391 (20) 485 (25) 310 (23) 371 (27) 134 (19) 174 (25) 256 (21) 299 (24) 
5. None of the time 1135 (59) 920 (47) 699 (51) 531 (38) 441 (64) 363 (52) 669 (55) 545 (45) 
Q2. Shortness of breath Evaluable, n 1936 1957 1373 1399 689 699 1214 1223 
1. More than once a day 224 (12) 332 (17) 193 (14) 301 (22) 71 (10) 83 (12) 150 (12) 243 (20) 
2. Once a day 161 (8) 204 (10) 144 (10) 161 (12) 43 (6) 66 (9) 115 (9) 135 (11) 
3. 3 to 6 times a week 188 (10) 256 (13) 159 (12) 200 (14) 58 (8) 91 (13) 127 (10) 161 (13) 
4. Once or twice a week 767 (40) 801 (41) 538 (39) 548 (39) 263 (38) 304 (43) 493 (41) 479 (39) 
5. Not at all 596 (31) 364 (19) 339 (25) 189 (14) 254 (37) 155 (22) 329 (27) 205 (17) 
Evaluable, n 1936 1957 1373 1399 689 699 1214 1223 
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Q3. Asthma symptoms woken up at 
night or earlier than usual 
1. 4 or more nights a week 144 (7) 206 (11) 130 (9) 186 (13) 46 (7) 62 (9) 95 (8) 141 (12) 
2. 2 to 3 nights a week 182 (9) 253 (13) 162 (12) 211 (15) 59 (9) 78 (11) 120 (10) 170 (14) 
3. Once a week 90 (5) 117 (6) 80 (6) 103 (7) 17 (2) 41 (6) 72 (6) 74 (6) 
4. Once or twice 340 (18) 397 (20) 266 (19) 310 (22) 131 (19) 133 (19) 204 (17) 255 (21) 
5. Not at all 1180 (61) 984 (50) 735 (54) 589 (42) 436 (63) 385 (55) 723 (60) 583 (48) 
Q4. Used rescue inhaler or 
nebulizer medication 
Evaluable, n 1936 1957 1373 1399 689 699 1214 1223 
1. 3 or more times per day 165 (9) 301 (15) 148 (11) 264 (19) 43 (6) 87 (12) 117 (10) 208 (17) 
2. 1 or 2 times per day 380 (20) 553 (28) 318 (23) 442 (32) 102 (15) 189 (27) 272 (22) 353 (29) 
3. 2 or 3 times a week 413 (21) 449 (23) 305 (22) 321 (23) 145 (21) 167 (24) 263 (22) 272 (22) 
4. Once a week or less 532 (27) 413 (21) 353 (26) 243 (17) 210 (30) 167 (24) 312 (26) 242 (20) 
5. Not at all 446 (23) 241 (12) 249 (18) 129 (9) 189 (27) 89 (13) 250 (21) 148 (12) 
Q5. Asthma control Evaluable, n 1936 1957 1373 1399 689 699 1214 1223 
1. Not controlled at all 24 (1) 33 (2) 21 (2) 30 (2) 8 (1) 9 (1) 16 (1) 24 (2) 
2. Poorly controlled 87 (4) 113 (6) 76 (6) 106 (8) 25 (4) 26 (4) 60 (5) 84 (7) 
3. Somewhat controlled 331 (17) 498 (25) 287 (21) 421 (30) 96 (14) 149 (21) 230 (19) 336 (27) 
4. Well controlled 893 (46) 870 (44) 647 (47) 613 (44) 309 (45) 323 (46) 567 (47) 535 (44) 
5. Completely controlled 601 (31) 443 (23) 342 (25) 229 (16) 251 (36) 192 (27) 341 (28) 244 (20) 
aICS and ICS/LABA subsets of the overall study population; bPatients whose asthma maintenance therapy at baseline per randomization stratification was ICS alone and pre-
randomization prescription was ICS alone; cPatients whose asthma maintenance therapy at baseline per randomization stratification was ICS/LABA and pre-randomization 
prescription was ICS/LABA. 
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Supplementary Table 2 
Transitional probability of asthma control status (based on ACT scores) in a recorded visit 
according to control status in the previous visit (overall study population; FF/VI n = 2114; UC 




Baseline to  
Week 12 
Week 12 to  
Week 24 
Week 24 to  
Week 40 
Week 40 to  
Week 52 
FF/VI UC FF/VI UC FF/VI UC FF/VI UC 
WC to WC n = 572 
86.7 
n = 583 
80.9 
n = 1163 
77.2 
n = 883 
68.8 
n = 1102 
76.3 
n = 857 
67.7 
n = 1063 
77.2 
n = 841 
68.8 
WC to PC n = 572 
9.3 
n = 583 
13.0 
 n = 1163 
15.4 
n = 883 
20.2 
n = 1102 
15.9 
n = 857 
20.8 
n = 1063 
15.4 
n = 841 
20.2 
WC to UnC n = 572 
4.0 
n = 583 
6.0 
n = 1163 
7.5 
n = 883 
11.0 
n = 1102 
7.8 
n = 857 
11.5 
n = 1063 
7.5 
n = 841 
11.0 
PC to WC n = 625 
60.8 
n = 631 
50.3 
n = 377 
44.6 
n = 507 
34.4 
n = 362 
43.4 
n = 464 
33.3 
n = 385 
44.6 
n = 458 
34.4 
PC to PC n = 625 
26.0 
 n = 631 
30.8 
n = 377 
32.7 
n = 507 
34.5 
 n = 362 
33.0 
n = 464 
34.5 
n = 385 
32.7 
n = 458 
34.5 
PC to UnC n = 625 
13.2 
 n = 631 
19.0 
n = 377 
22.7 
n = 507 
31.1 
n = 362 
23.6 
n = 464 
32.2 
n = 385 
22.7 
n = 458 
31.1 
UnC to WC n = 812 
35.4 
n = 818 
26.3 
n = 346 
22.1 
n = 525 
15.6 
n = 363 
21.3 
n = 543 
15.0 
n = 390 
22.2 
n = 571 
15.6 
UnC to PC n = 812 
28.8 
n = 818 
27.6 
n = 346 
26.1 
n = 525 
22.1 
n = 363 
25.7 
n = 543 
21.6 
n = 390 
26.1 
n = 571 
22.1 
UnC to UnC n = 812 
35.8 
n = 818 
46.1 
n = 346 
51.8 
n = 525 
62.2 
n = 363 
53.0 
n = 543 
63.4 
n = 390 
51.8 
n = 571 
62.2 
Individual patient numbers refer to patients with the specific control status at the index visit who had a 
recorded ACT total score in the following visit.  
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aAsthma control status based on ACT scores.  
bProbabilities were calculated using an ordinal logistic regression model adjusted for randomized 
treatment and previous control status.  
Abbreviations: ACT, Asthma Control Test; FF/VI, fluticasone furoate/vilanterol; PC, partially controlled; 
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Supplementary Table 3 
Transitional probability of asthma control status (based on ACT scores) in a recorded visit 
according to control status in the previous visit (ICS subset of overall study population; FF/VI 




Baseline to  
Week 12 
Week 12 to  
Week 24 
Week 24 to  
Week 40 
Week 40 to  
Week 52 
FF/VI UC FF/VI UC FF/VI UC FF/VI UC 
WC to WC n = 255 
88.3 
n = 255 
82.1 
n = 476 
80.0 
n = 361 
71.0 
n = 433 
80.4 
n = 352 
71.6 
n = 432 
81.2 
n = 347 
72.5 
WC to PC n = 255 
8.3 
n = 255 
12.4 
n = 476 
13.7 
n = 361 
19.2 
n = 433 
13.5 
n = 352 
18.9 
n = 432 
13.0 
n = 347 
18.3 
WC to UnC n = 255 
3.4 
n = 255 
5.5 
n = 476 
6.2 
n = 361 
9.8 
n = 433 
6.1 
n = 352 
9.6 
n = 432 
5.8 
n = 347 
9.1 
PC to WC n = 239 
65.8 
n = 247 
54.1 
n = 103 
50.7 
n = 176 
38.6 
n = 105 
51.3 
n = 160 
39.2 
n = 118 
52.6 
n = 157 
40.4 
PC to PC n = 239 
23.5 
n = 247 
29.6 
n = 103 
31.1 
n = 176 
34.7 
n = 105 
30.8 
n = 160 
34.5 
n = 118 
30.3 
n = 157 
34.3 
PC to UnC n = 239 
10.6 
n = 247 
16.3 
n = 103 
18.3 
n = 176 
26.7 
n = 105 
17.9 
n = 160 
26.2 
n = 118 
17.2 
n = 157 
25.3 
UnC to WC n = 217 
40.7 
n = 223 
29.6 
n = 95 
26.8 
n = 146 
18.3 
n = 105 
27.3 
n = 150 
18.7 
n = 86 
28.3 
n = 161 
19.5 
UnC to PC n = 217 
28.5 
n = 223 
28.3 
n = 95 
27.7 
n = 146 
24.0 
n = 105 
27.8 
n = 150 
24.3 
n = 86 
28.1 
n = 161 
24.7 
UnC to UnC n = 217 
30.8 
n = 223 
42.1 
n = 95 
45.5 
n = 146 
57.7 
n = 105 
44.8 
n = 150 
57.0 
n = 86 
43.6 
n = 161 
55.9 
Individual patient numbers refer to patients with the specific control status at the index visit who had a 
recorded ACT total score in the following visit.  
aControl status based on ACT scores.  
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bProbabilities were calculated using an ordinal logistic regression model adjusted for randomized 
treatment and previous control status.  
Abbreviations: ACT, Asthma Control Test; FF/VI, fluticasone furoate/vilanterol; ICS, inhaled 
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Supplementary Table 4 
Transitional probability of asthma control status (based on ACT scores) in a recorded visit 
according to control status in the previous visit (ICS/LABA subset of overall study population; 




Baseline to  
Week 12 
Week 12 to  
Week 24 
Week 24 to  
Week 40 
Week 40 to  
Week 52 
FF/VI UC FF/VI UC FF/VI UC FF/VI UC 
WC to WC n = 309 
85.3 
n = 322 
79.4 
n = 665 
75.3 
n = 506 
66.9 
n = 648 
73.2 
n = 493 
64.4 
n = 608 
74.7 
n = 477 
66.2 
WC to PC n = 309 
10.2 
n = 322 
14.0 
n = 665 
16.5 
n = 506 
21.2 
n = 648 
17.7 
n = 493 
22.4 
n = 608 
16.8 
n = 477 
21.6 
WC to UnC n = 309 
4.5 
n = 322 
6.6 
n = 665 
8.3 
n = 506 
11.9 
n = 648 
9.1 
n = 493 
13.1 
n = 608 
8.5 
n = 477 
12.3 
PC to WC n = 369 
58.0 
n = 373 
47.8 
n = 270 
41.9 
n = 319 
32.4 
 n = 253 
39.3 
n = 291 
30.1 
 n = 261 
41.2 
n = 293 
31.7 
PC to PC n = 369 
27.4 
n = 373 
31.6 
n = 270 
33.4 
n = 319 
34.5 
n = 253 
33.9 
n = 291 
34.4 
n = 261 
33.5 
n = 293 
34.5 
PC to UnC n = 369 
14.7 
n = 373 
20.5 
n  = 270 
24.7 
n = 319 
33.1 
n = 253 
26.8 
n = 291 
35.5 
n = 261 
25.3 
n = 293 
33.8 
UnC to WC n = 583 
33.0 
n = 575 
24.7 
n = 245 
20.5 
n = 372 
14.6 
n = 251 
18.8 
n = 385 
13.3 
n = 300 
20.0 
n = 405 
14.2 
UnC to PC n = 583 
28.9 
n = 575 
27.2 
n = 245 
25.4 
n = 372 
21.4 
n = 251 
24.5 
n = 385 
20.3 
n = 300 
25.2 
n = 405 
21.1 
UnC to UnC n = 583 
38.1 
n = 575 
48.1 
n = 245 
54.1 
n = 372 
64.0 
n = 251 
56.8 
n = 385 
66.4 
n = 300 
54.9 
n = 405 
64.7 
Individual patient numbers refer to patients with the specific control status at the index visit who had a 
recorded ACT total score in the following visit.  
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aControl status based on ACT scores.  
bProbabilities were calculated using an ordinal logistic regression model adjusted for randomized 
treatment and previous control status.  
Abbreviations: ACT, Asthma Control Test; FF/VI, fluticasone furoate/vilanterol; ICS/LABA; inhaled 
corticosteroid/long-acting beta2 agonist combination; PC, partially controlled; UC, usual care; UnC, 
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Supplementary Table 5 
Statistical analysis of the proportion of respondersa on individual EQ-5D-3L descriptive 










Baseline Week 52b 
Patients, n/N (%) Patients, n/N (%)  





n = 750 
UC 
n = 755 
FF/VI 
n = 750 
UC 
n = 755 











p = .013 











p = .273 











p = .697 



























p = .140 
aResponders were defined as patients who self-scored 1 = no problems for a given dimension.  
bData based on last available on-treatment measurement (Week 52 or early withdrawal visit).  
cORs, 95% CIs, and p-values were calculated using a logistic regression model adjusted for randomized 
treatment, ACT total score at baseline per randomization stratification, gender, age, and the relevant baseline 
EQ-5D-3L domain score.   
Abbreviations: CI, confidence interval; EQ-5D-3L, EuroQol 5-Dimensions 3-Levels Questionnaire; FF/VI, 
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Supplementary Table 6 
Statistical analysis of the proportion of respondersa on individual EQ-5D-3L descriptive 










Baseline Week 52b 
Patients, n/N (%) Patients, n/N (%)  





n = 1325 
UC 
n = 1325 
FF/VI 
n = 1325 
UC 
























p = .913 











p = .006 



























p = .366 
aResponders were defined as patients who self-scored 1 = no problems for a given dimension.  
bData based on last available on-treatment measurement (Week 52 or early withdrawal visit).  
cORs, 95% CIs, and p-values were calculated using a logistic regression model adjusted for randomized 
treatment, ACT total score at baseline per randomization stratification, gender, age, and the relevant baseline 
EQ-5D-3L domain score.   
Abbreviations: CI, confidence interval; EQ-5D-3L, EuroQol 5-Dimensions 3-Levels questionnaire; FF/VI, 









Supplementary Fig. 1. Transitional probabilities of worsening asthma control based on ACT scores measured 
across the 12-month study period.a,b (A) Overall study population, (B) ICS subset, (C) ICS/LABA subset. 
aTransitional probability of control status in any visit according to control status in the previous visit. bProbabilities 
were calculated using an ordinal logistic regression model adjusted for randomized treatment and previous 
control status. (A) Overall study population: data based on n = 2052 patients in the FF/VI group and n = 2076 in 
the UC group contributing to at least 1 transition. (B) ICS subset: data based on n = 724 patients in the FF/VI 
group and n = 743 in the UC group contributing to at least 1 transition. (C) ICS/LABA subset: data based on n = 
1290 patients in the FF/VI group and n = 1296 in the UC group contributing to at least 1 transition. Abbreviations: 
FF/VI, fluticasone furoate/vilanterol; PC, partially controlled; UC, usual care; UnC, uncontrolled; WC, well 
controlled. 
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Supplementary Fig. 2. Transitional probabilities of remaining uncontrolled or partially controlled based on ACT 
scores measured across the 12-month study period.a, b (A) Overall study population, (B) ICS subset, (C) 
ICS/LABA subset. aTransitional probability of control status in any visit according to control status in the previous 
visit. bProbabilities were calculated using an ordinal logistic regression model adjusted for randomized treatment 
and previous control status. (A) Overall study population: data based on n = 2052 patients in the FF/VI group and 
n = 2076 in the UC group contributing to at least 1 transition. (B) ICS subset: data based on n = 724 patients in 
the FF/VI group and n = 743 in the UC group contributing to at least 1 transition. (c) ICS/LABA subset: data 
based on n = 1290 patients in the FF/VI group and n = 1296 in the UC group contributing to at least 1 transition. 
Abbreviations: FF/VI, fluticasone furoate/vilanterol; PC, partially controlled; UC, usual care; UnC, uncontrolled. 
